Sagimet Biosciences Inc. Operating Lease, Payments, Use
Sagimet Biosciences Inc. (SGMT) reported Operating Lease, Payments, Use of $159.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePaymentsUse · last filed 2026-03-11
- Sagimet Biosciences Inc. operating lease, payments, use for the quarter ending 2023-12-31 was $40.00K, a 2.56% increase year-over-year.
- Sagimet Biosciences Inc. operating lease, payments, use for the quarter ending 2023-09-30 was $40.00K, a 2.56% increase year-over-year.
- Sagimet Biosciences Inc. operating lease, payments, use for the quarter ending 2022-12-31 was $39.00K.
- Sagimet Biosciences Inc. operating lease, payments, use for the quarter ending 2022-09-30 was $39.00K.
- Sagimet Biosciences Inc. operating lease, payments, use for fiscal 2025 was $159.00K, a 0.00% change from fiscal 2024.
- Sagimet Biosciences Inc. operating lease, payments, use for fiscal 2024 was $159.00K, a 0.63% increase from fiscal 2023.
- Sagimet Biosciences Inc. operating lease, payments, use for fiscal 2023 was $158.00K, a 0.64% increase from fiscal 2022.
- Sagimet Biosciences Inc. operating lease, payments, use for fiscal 2022 was $157.00K.
| Period end | Operating Lease, Payments, Use 3 month | Operating Lease, Payments, Use 6 month | Operating Lease, Payments, Use 9 month | Operating Lease, Payments, Use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $159.00K 10-K · filed 2026-03-11 | |||
| 2024-12-31 | $159.00K 10-K · filed 2026-03-11 | |||
| 2023-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $80.00K derived: sum of 2 quarters · filed 2025-03-12 | $158.00K 10-K · filed 2025-03-12 | |
| 2023-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $118.00K 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $78.00K 10-Q · filed 2023-08-21 | |||
| 2022-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $78.00K derived: sum of 2 quarters · filed 2024-03-25 | $157.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $118.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $79.00K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |